Focused On-demand Library for CXXC-type zinc finger protein 1

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
Q9P0U4

UPID:
CXXC1_HUMAN

ALTERNATIVE NAMES:
CpG-binding protein; PHD finger and CXXC domain-containing protein 1

ALTERNATIVE UPACC:
Q9P0U4; B2RC03; Q8N2W4; Q96BC8; Q9P2V7

BACKGROUND:
The CXXC-type zinc finger protein 1, known for its alternative names such as CpG-binding protein and PHD finger and CXXC domain-containing protein 1, is a transcriptional activator. It exhibits a unique DNA binding specificity for unmethylated CpG motifs, favoring CpGG sequences. This specificity indicates a crucial role in the regulation of gene expression through epigenetic mechanisms.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of CXXC-type zinc finger protein 1 offers a promising pathway to novel therapeutic approaches. Its ability to specifically bind to unmethylated CpG motifs suggests its involvement in critical regulatory processes, which could be targeted in therapies aimed at correcting gene expression anomalies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 7688 of 8789